Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

RA Capital Management Bets Another $20 Million On Kala Pharmaceuticals Inc.

Peter Kolchinsky’s RA Capital purchased $20 million of Kala Pharmaceuticals Inc. (KALA) shares. The details of the transaction can be seen below:

Peter Kolchinsky
Peter Kolchinsky
RA Capital Management

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
RA Capital Management 0 4,537,478 0 4,537,478 4,537,478 14.1%
Peter Kolchinsky 0 4,537,478 0 4,537,478 4,537,478 14.1%

Page 1 of 5 – SEC Filing



Washington, D.C. 20549


OMB Number:     3235-0145

Expires:   February 28, 2009

Estimated average burden

hours per response…   10.4



Under the Securities Exchange Act of 1934


(Amendment No. 1)*


Kala Pharmaceuticals,
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
(CUSIP Number)

RA Capital Management, LLC

20 Park Plaza, Suite 1200

Boston, MA 02116

Telephone: 617.778.2512

Attn: Peter Kolchinsky

(Name, Address and Telephone Number of Person
Authorized to
Receive Notices and Communications)

  October 3, 2018
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Kala Pharmaceuticals Inc.
Trade (KALA) Now!